title: Heparin-induced Thrombocytopenia Presenting With Deep Venous Thrombosis and Pulmonary Embolism Successfully Treated With Rivaroxaban: Clinical Case Report and Review of Current Experiences.
abstract: Heparin-induced thrombocytopenia (HIT) is a life or limb-threatening thrombotic thrombocytopenia. HIT is traditionally treated with factor-IIa inhibitors such as bivalirudin, lepirudin, or argatroban. However, these agents usually require parenteral administration and are not generally available in all countries. Recently, several experiences with novel oral anticoagulants (NOACs) administration to treat HIT had been reported. NOACs generally offer advantages such as consistent and predictable anticoagulation, oral administration with good patient compliance, and a good safety profile. We report a case of HIT with severe thrombotic complications successfully treated with rivaroxaban and discuss the current knowledge about the use of NOACs for the treatment of this potentially fatal thrombocytopenia.
authors.affiliation: *Department of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovak Republic; †Division of Molecular Medicine, BioMed Martin, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovak Republic; and ‡Department of Hematology and Blood Transfusion, Jessenius Faculty of Medicine in Martin, National Center of Hemostasis and Thrombosis, Comenius University in Bratislava, Martin, Slovak Republic.
authors.forename: Matej
authors.initials: M
authors.lastname: Samoš
authors.forename: Tomáš
authors.initials: T
authors.lastname: Bolek
authors.forename: Jela
authors.initials: J
authors.lastname: Ivanková
authors.forename: Lucia
authors.initials: L
authors.lastname: Stančiaková
authors.forename: František
authors.initials: F
authors.lastname: Kovář
authors.forename: Peter
authors.initials: P
authors.lastname: Galajda
authors.forename: Peter
authors.initials: P
authors.lastname: Kubisz
authors.forename: Ján
authors.initials: J
authors.lastname: Staško
authors.forename: Marián
authors.initials: M
authors.lastname: Mokáň
mesh_terms: D000925:Anticoagulants / Q000009:adverse effects; D003937:Diagnosis, Differential; D065427:Factor Xa Inhibitors / Q000627:therapeutic use*; D005260:Female; D006493:Heparin / Q000009:adverse effects*; D006801:Humans; D008875:Middle Aged; D011655:Pulmonary Embolism / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy*; D000069552:Rivaroxaban / Q000627:therapeutic use*; D013921:Thrombocytopenia / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy*; D016896:Treatment Outcome; D020246:Venous Thrombosis / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy*
chemical_list: D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D006493:Heparin; D000069552:Rivaroxaban